<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31977278</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination.</ArticleTitle><Pagination><StartPage>1595</StartPage><EndPage>1601</EndPage><MedlinePgn>1595-1601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2020.1711678</ELocationID><Abstract><AbstractText Label="BACKGROUND">Short-term dynamic changes in neutralizing antibodies against EV71 and EV71-IgM after inactivated EV71 vaccine injection are unknown.</AbstractText><AbstractText Label="METHODS">This study was designed as a randomized, open-label study and was registered at ClinicalTrials.gov (NCT03278132). In total, 120 healthy infants aged 6-35&#xa0;months were randomized 1:1:1 to provide a second blood sample on day 10, day 20, or day 30 after the first vaccine dose, respectively.</AbstractText><AbstractText Label="RESULTS">According to the per-protocol set, a rapid immune response against EV71 was observed 10&#xa0;days after the first EV71 vaccine dose, with antibody titers &#x2265;1:8 in 89.19% of participants (95% CI: 74.58-96.97%) on day 10, in 80.65% (95% CI: 62.53-92.55%) on day 20, in 66.67% (95% CI: 49.03-81.44%) on day 30, and in 100% (95% CI: 96.52%-.) on day 60. Based on an ELISA, the percentages of participants positive for EV71-IgM on day 0 and day 60 were 1.71% (2 out of 117) and 82.86% (87 out of 105), respectively.</AbstractText><AbstractText Label="CONCLUSIONS">The EV71 vaccine could be used for contingency vaccination to further control EV71-associated disease outbreaks. Caution should be taken in using the EV71-IgM test for rapid EV71 infection diagnosis after EV71 vaccine administration.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">ClinicalTrials.gov NCT03278132.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shenyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Ji</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8171-5195</Identifier><AffiliationInfo><Affiliation>Clinical Research Department, Sinovac Biotech Co., Ltd , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinpei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shangyu District Center for Disease Control and Prevention , Shaoxing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Zhengkai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunization Programme, Xiuzhou District Center for Disease Control and Prevention , Jiaxing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jianqiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shangyu District Center for Disease Control and Prevention , Shaoxing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yingping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenzhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaosong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Research Department, Sinovac Biotech Co., Ltd , Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Huakun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunization Programme, Zhejiang Provincial Center for Disease Control and Prevention , Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03278132</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV71 vaccine</Keyword><Keyword MajorTopicYN="N">EV71-IgM</Keyword><Keyword MajorTopicYN="N">rapid response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31977278</ArticleId><ArticleId IdType="pmc">PMC7482867</ArticleId><ArticleId IdType="doi">10.1080/21645515.2020.1711678</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization Western Pacific Region . A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Manila: World Health Organization Western Pacific Region; [accessed 2019 April10]. https://iris.wpro.who.int/bitstream/handle/10665.1/5521/9789290615255_eng.pdf.</Citation></Reference><Reference><Citation>Chinese center for disease control and prevention . National notifiable disease reported system (HFMD) from 2008 to 2017. http://www.chinacdc.cn/jkzt/crb/bl/szkb/cbw_2274/. Accessed 10April 2019.</Citation></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY.. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics. 2007;120:e244&#x2013;52. doi:10.1542/peds.2006-3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang J-R, Shih S-R. An epidemic of enterovirus 71 infection in Taiwan. Taiwan enterovirus epidemic working group. N Engl J Med. 1999;341:929&#x2013;35. doi:10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih S-R, Liu -C-C, Wu M-H. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis. 2002;34(Suppl 2):S52&#x2013;7. doi:10.1086/338819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338819</ArticleId><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis. 2003;9:291&#x2013;93. doi:10.3201/eid0903.020285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0903.020285</ArticleId><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;32. doi:10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, Clear D, Del Sel S, Chieng CH, Tio PH, Cardosa MJ, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis. 2009;9:3. doi:10.1186/1471-2334-9-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-9-3</ArticleId><ArticleId IdType="pmc">PMC2637878</ArticleId><ArticleId IdType="pubmed">19152683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Podin Y, Akin W, Del Sel S, Mohan A, Chieng C, Perera D, Clear D, Wong D, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44:646&#x2013;56. doi:10.1086/522508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/522508</ArticleId><ArticleId IdType="pubmed">17278054</ArticleId></ArticleIdList></Reference><Reference><Citation>An ZJ, Liu Y, Liao QH, et al. Guidelines for use of inactivated enterovirus type 71 vaccine. Chin J Vacc Immun. 2016;6(4):458&#x2013;64 .</Citation></Reference><Reference><Citation>China Food and Drug Administration . The standard guidelines for adverse reactions grading of vaccine clinical trials. [accessed 2019 April10]. http://wwwsdagovcn/WS01/CL0844/9350_5html.</Citation></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829&#x2013;37. doi:10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818&#x2013;28. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum Vaccin Immunother. 2018;14:1517&#x2013;23. doi:10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC. Two-year efficacy and immunogenicity of Sinovac enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15:129&#x2013;37. doi:10.1586/14760584.2016.1096782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy chinese children: a randomized open-label study. J Infect Dis. 2017;215:56&#x2013;63. doi:10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Li J, Zhang X, Meng F, Zhou Y, Yao X, Gan Z, Zhu F. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6&#x2013;35 months. Hum Vaccin Immunother. 2016;12:916&#x2013;21. doi:10.1080/21645515.2015.1118595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1118595</ArticleId><ArticleId IdType="pmc">PMC4962943</ArticleId><ArticleId IdType="pubmed">26751765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, Zeng Y, Fan R, Zhao D, Ma W, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and group A meningococcal polysaccharide vaccine: a phase 4, open-label, single-center, randomized, noninferiority trial. J Infect Dis. 2019;220:392&#x2013;99. doi:10.1093/infdis/jiz129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, Gao F, Yang L, Yao X, Shao J, et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children. PLoS One. 2013;8:e79599. doi:10.1371/journal.pone.0079599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren YH, Chen JT, Wu WT. Evaluation on different immunization schedules of hepatitis A vaccine healive. Chin J Vaccines Immun. 2003;9:219&#x2013;21.</Citation></Reference><Reference><Citation>Wang DM, Shi ZH, Zhu HM. The observation of antibody dynamic in children who inactivated hepatitis A vaccine Chinese. J Vaccines Immunization. 2010;16(1):4&#x2013;4.</Citation></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao Q-Y, Wen S-Q, Huang R-G, Hu Y-S, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2014;209:46&#x2013;55. doi:10.1093/infdis/jit429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of People&#x2019;s Republic of China . The guidelines for the diagnosis and treatment of hand foot and mouth disease; 2018. edition.</Citation></Reference><Reference><Citation>MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E, Cook MC, Vinuesa CG. Extrafollicular antibody responses. Immunol Rev. 2003;194:8&#x2013;18. doi:10.1034/j.1600-065X.2003.00058.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-065X.2003.00058.x</ArticleId><ArticleId IdType="pubmed">12846803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>